As discussed, OPN binds to several integrin receptors including α4β1, α9β1, and α9β4 expressed by leukocytes. These receptors have been well-established

to function in cell adhesion, migration, and survival in these cells. Therefore, recent research efforts have focused on the role of OPN in mediating such responses [14]. OPN gene transcription in bone tissue is regulated by the interaction between transactivating factors and vitamin D3 responsive elements [15]. Previous study has confirmed that OPN is overexpressed in the NSCLC tumor tissues compared to adjacent normal counterparts; and its overexpression is significantly correlated with TNM stages and lymph metastasis [16]. However

there are no relative reports about the relationship between OPN polymorphisms with survival of NSCLC and risk of bone metastasis currently. In the present study, we recruited see more 360 NSCLC patients and 360 cancer-free control, aim to investigate whether OPN-66 T/G, -156G/GG, and -443C/T genotypes affect the survival of patients; meanwhile to determine whether they have an association with incidence of bone metastasis development. Patients and methods Patients Three hundred sixty ambulatory patients with stage I to IV lung cancer patients who were admitted to the College of Medicine of Shan Dong selleck chemicals University, Qi Lu Hospital in Jinan, China between www.selleckchem.com/products/BafilomycinA1.html October 2003 and July 2007 were studied. 79 patients with bone metastasis acetylcholine and

281 patients without bone metastasis were included in this study. The median age was 57.21 years (range, 24 to 81 years); 199 patients were male and 161 patients were female. The diagnosis of lung cancer was confirmed cytologically or histologically. All patients gave their informed consent to the diagnostic procedures. The TNM stage mentioned in the current study was diagnosed at first hospitalization. Healthy control group consisted of a random sample of 360 ethnic Han Chinese from Shan Dong province. Bone metastasis evaluation: All patients were evaluated for bone metastasis by bone scintigraphy. A total of 25 mCi 99mTechnetium methylene diphosphonates (MDP) was injected intravenously, and front and back images of the whole body were taken after 3 hours. The apparatus used was a double-detector gamma camera (VERTEX, ADAC Co., CA, USA). Bone scintigraphy was read by two radiologists and classified into either a bone metastasis-positive or a negative group. When the bone scintigraphic interpretation differed among radiologists, positive scans were further assessed by additional radiographs; computerized tomography, magnetic resonance imaging, positron emission tomography or bone biopsy, except when the increased uptake was recognized as being due to a benign condition [17, 18].